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Abstract
Preterm labour continues to be a major contributor to neonatal and infant morbidity. Recent data
from the USA indicate that the number of preterm deliveries (including those associated with
preterm labour) has risen in the last 20 years by 30%. This increase is despite considerable efforts
to introduce new therapies for the prevention and treatment of preterm labour and highlights the
need to assess research in this area from a fresh perspective. In this paper we discuss i) the
limitations of our knowledge concerning prediction, prevention and treatment of preterm labour
and ii) future multidisciplinary strategies for improving our approach.
Background
Preterm labour continues to be a major contributor to
neonatal and infant morbidity. Recent data from the USA
indicate that the number of preterm deliveries (including
those associated with preterm labour) has risen in the last
20 years by 30% (from 9.4% to 12.5%) [1,2], with the
highest rates still affecting ethnic and racial minorities and
women of low socio-economic status. This increase,
despite considerable efforts to introduce new therapies for
the prevention and treatment of preterm labour, high-
lights the need to assess research in this area from a fresh
perspective.
Part of the problem is that preterm labour is a syndrome
of multiple aetiologies influenced by a wide number of
genetic, biological/biophysical, psychosocial and envi-
ronmental factors (Figure 1). The emerging consensus is
that future research efforts need to focus on improving
our ability to predict and diagnose preterm labour by
increasing our understanding of the pathophysiological
mechanisms involved. A greater mechanistic understand-
ing of preterm labour, coupled with better tools for pre-
diction, would undoubtedly contribute to the appropriate
stratification of women into risk groups and facilitate the
development of targeted therapeutic agents and timing of
clinical intervention. Such studies, however, require a
multidisciplinary outlook and a co-ordinated approach to
planning and funding research programmes.
Mediators and mechanisms
For reasons described above, it is highly unlikely that
there is one underlying mechanism that will explain pre-
term labour in all women. However, two contributory
processes of current interest include the influence of infec-
tion and inflammation, and uterine stretch on myome-
trial contractility [for details see [3]]. Infection or sub
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clinical infection is thought to occur in at least 40% of pre-
term deliveries and more frequently with births that occur
below 26 weeks [4] and uterine stretch is proposed to
influence uterine contractility to a greater degree in multi-
ple pregnancy. Our understanding of these, and other
processes associated with preterm labour, is still relatively
limited, although microarray and proteomic studies of
uterine tissues and fluids should provide further insight
and novel research directions. However, subsequent
determination of the functional impact of any mRNA and
protein changes will be fundamental to future progress.
Similarly, the complex interplay of these processes in dif-
ferent uterine tissues (e.g. cervix, fetal membranes, decid-
uas and myometrium), as well as the influence of
maternal/fetal genetics and environment, will also require
in-depth investigation.
Prediction and identification of women at risk of preterm 
labour
A large number of studies have attempted to identify a sin-
gle, or combination of biomarkers (e.g. cytokines, fetal
fibronectin etc.) and physical measurements (cervical
length) for the detection of women at risk of preterm
labour (Table 1) [4-6]. Of interest is the number of
inflammation related biomarkers that have been identi-
fied. However, the limitation of such data, with the excep-
tion a few studies of fetal fibronectin and bacterial
vaginosis studies, is that often measurements have been
obtained from a single clinical visit at 20–24 weeks' gesta-
tion, which at best can provide a snap shot of dynamic
processes. Also, the timing of measurements is not neces-
sarily optimal for the detection (and treatment) of women
destined to go into early preterm labour (< 26 weeks'). Of
the myriad markers identified, only cervical length and
bedside fetal fibronectin measurement appear to be
adopted into research based clinical practice in the UK. As
a result, there remains a reliance on previous pregnancy
history for the identification of high-risk women within
current antenatal care, which precludes the identification
of women in their first pregnancy.
Advances in '-omic' technology (proteomics, metabo-
lomics, peptidomics) may offer an alternative strategy for
detection of women at risk of preterm labour regardless of
parity [7,8]. Indeed, several informative peptides have
been reported, including calgranulins, and defensins,
using this approach [9-12]. Currently, these investigations
tend to be limited to analysis of single biological samples
from women either in established preterm labour or
known to be of increased risk. Future studies would bene-
fit from collecting serial samples from women in order to
gain mechanistic insight into disease progression, as well
as identifying candidate biomarkers for testing in low risk
populations.
Tocolytic and prophylatic treatment of women
Despite an incomplete understanding of mechanisms
underlying preterm labour, a plethora of different inter-
vention strategies have been attempted. Administration of
tocolytics in symptomatic women achieves at best only
one or two days extension of gestation, and none of the
classes of drugs in clinical use is clearly more effective than
any other [13]. Results from recent trials of prophylactic
therapy (e.g. prostaglandin endoperoxide synthase 2
(PTGS2) inhibitors and antibiotics) [14-18], with the
exception of vaginal progesterone [19,20], have been dis-
appointing. This may be, in part, due to our inability to
identify those women most likely to benefit from treat-
ment and a lack of consensus as to when to intervene, a
situation that would be greatly improved by more knowl-
edge of the pathophysiological events involved.
Current translational research strategy
Our approach to preterm labour research attempts to
address some of the criticisms raised above. With support
of Tommy's the baby charity, we have created a multidis-
ciplinary environment for pregnancy research which
encourages bidirectional interactions between scientists
and clinicians. Our current strategy has resulted in the
development of common research themes and collabora-
tive translational studies to address scientific and clinical
questions concurrently. One such theme is the under-
standing the role that inflammatory mediators play in
preterm labour (Figure 2).
Basic research studies have concentrated on the mecha-
nisms by which the pro-inflammatory cytokine inter-
leukin (IL) 1B might influence uterine smooth muscle
excitability. It is well documented that inflammatory
cytokines stimulates PTGS2 expression and prostaglandin
synthesis in human myometrium [21,22]. However, in
light of the disappointing clinical results studies using
PTGS2 inhibitors [14], our focus has been on the alterna-
Preterm labour is a complex syndrome of multiple aetiolo- gies requiring a multidisciplinary research approach Figure 1
Preterm labour is a complex syndrome of multiple aetiolo-
gies requiring a multidisciplinary research approach.
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tive pathways, particularly transient receptor potential cat-
ion channel subfamily C proteins (TRPC1-7; that can
form calcium entry channels), by which cytokines may
influence uterine contractility (Figure 3). The TRPC gene
family encode for proteins that form cation entry chan-
nels associated with store operated calcium entry (also
known as capacitative calcium entry) and receptor/basal
calcium entry channels [23]. The activation of such chan-
nels is responsible for mediating a wide range of physio-
logical processes including augmentation of agonist-
induced contraction, cell growth and calcium sensitive
induced changes in gene expression [23]. TRPC proteins
have been identified in both lower and upper segment tis-
sue and cells [24-27]. We have demonstrated a significant
increase in TRPC3, 4 and 6 protein in myometrial tissue
from women in labour and have subsequently investi-
gated potential stimuli responsible for inducing such
changes [26]. The working hypothesis proposes that
cytokines will i) induce calcium signals that regulate gene
expression of cellular proteins, including components of
the prostaglandin signalling cascade, that promote uterine
contraction and ii) specifically enhance expression of
pathways involved in increasing calcium availability for
contraction.
Our recent studies have clearly demonstrated that IL1B, at
concentration found in high vaginal swabs from women
in preterm labour, increases the excitability of human
uterine cells [28] within 24 hours of treatment. This tim-
ing is consistent with in vivo observations that IL1B
induces contractions in animals within a similar time-
frame [29]. Specifically, IL1B modulates protein expres-
sion of TRPC3 (a putative calcium channel) and SR Ca2+-
ATPases, initiates spontaneous [Ca2+]i  oscillations and
augments calcium influx pathways and a store operated
current [26,28]. Interestingly, the IL1B induced increase in
TRPC3 expression does not appear to be influenced by
PTGS2 mediated prostaglandin synthesis, as nimesulide
(a PTGS2 specific inhibitor) does not inhibit the response
[26]. However this does not rule out the possibility that
prostaglandins, arachidonic acid or components of the
prostaglandin-receptor mediated response stimulates cal-
cium entry via TRPC3 channels. The induction of TRPC3
protein expression by IL1B may in part explain the
increase in TRPC3 expression observed in uterine muscle
Schematic diagram to illustrate potential mechanisms by which infection/inflammation could influence uterine smooth muscle  culminating in premature labour Figure 2
Schematic diagram to illustrate potential mechanisms by which infection/inflammation could influence uterine 
smooth muscle culminating in premature labour. Aspects of this model are also relevant to the processes influencing 
the cervix and fetal membranes. FHPA, fetal hypothalamic pituitary adrenal axis; PG, prostaglandins.
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Table 1: Examples of the wide range of biochemical and 
biophysical markers associated with potential risk of preterm 
labour
Potential predictors of preterm birth
Bacterial vaginosis
Interleukin 6
Interleukin 1B
Interleukin 8
Tumor necrosis factor (TNF superfamily, member 2)
Colony stimulating factor 3
Relaxin
C-terminal propeptide of procollagen
Fetal fibronectin
α-fetoprotein
Salivary estriol
Cervical length
Electromyograph activity
Maternal body mass index
Previous history
Human chorionic gonadotrophin
Corticotrophin releasing hormone
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at labour onset and provides a plausible mechanism by
which cytokines could induce premature labour. This
work is being expanded upon in order to further dissect
the signalling cascade and determine whether inflamma-
tory agents enhance calcium signalling pathways and
modulate human myometrial tissue function.
To complement our scientific research, we have instigated
a new study (CLIC: a mechanistic investigation into cervi-
cal length and inflammatory changes; funded by Action
Medical Research). It is recognised that preterm labour is
often pre-empted by progressive asymptomatic cervical
shortening; inflammatory mediators (e.g. IL6, IL1B and
tumour necrosis factor) and matrix metalloproteinases are
implicated in this premature ripening of the cervix [30].
However, it remains unclear whether inflammatory
responses precede cervical shortening or are a conse-
quence of labour itself. This mechanistic longitudinal
study will address the question as to whether inflamma-
tion is associated with cervical shortening and if com-
monly used intervention impact on the process. Women
are being recruited from several high-risk preterm clinics
(in compliance with the Declaration of Helsinki, 1996)
[31] and a range of longitudinal biochemical and bio-
physical measurements recorded. A variety of 'omic' based
technologies will also be employed to provide insight into
the temporal nature of biochemical events and potentially
identify novel biomarkers for prediction of risk.
Conclusion
If we are to make any impact in the area of prevention,
prediction and treatment of preterm labour we need to
revisit our current strategies and develop a more multidis-
ciplinary approach to undertaking research in this area.
The experience of our collaborative grouping suggests that
close interactions between scientists and clinicians ena-
bles the development of common research themes tar-
geted at providing insight into one aspect of the complex
aetiology of preterm labour. It is anticipated that the
development of similar, but larger research networks will
Calcium entry pathways associated with TRPC proteins Figure 3
Calcium entry pathways associated with TRPC proteins. TRPC proteins are proposed to form store operated and 
basal/receptor operated plasma membrane calcium channels (depicted in green). Receptor operated calcium entry can occur 
when an agonist (e.g. oxytocin or PGF2α) binds to its receptor (R) resulting in an increase in diacylglycerol (DAG) and IP3 
(inositol 1,4,5-trisphosphate). Interaction of IP3 with the receptor (ITPR) causes release of calcium for the sarcoplasmic reticu-
lum (SR) and initiates store operated calcium entry.
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ultimately be the key to understanding the complete syn-
drome of preterm labour and the improvement of out-
comes for mothers and babies.
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